A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

BACKGROUND: Preclinical studies in breast cancer models showed that BRCA1 or BRCA2 deficient cell lines, when compared to BRCA proficient cell lines, are extremely sensitive to PARP1 inhibition. When combining the PARP1 inhibitor olaparib with cisplatin in a BRCA1-mutated breast cancer mouse model,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Trials
Auteurs principaux: Schouten, Philip C., Dackus, Gwen M. H. E., Marchetti, Serena, van Tinteren, Harm, Sonke, Gabe S., Schellens, Jan H. M., Linn, Sabine C.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915081/
https://ncbi.nlm.nih.gov/pubmed/27323902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-016-1423-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires